Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.

Background In hemodialysis (HD), switching from erythropoiesis-stimulating agent(ESA) originators to biosimilarsis associated with the need for doses approximately 10% higher, according to industry-driven studies.